Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI).
- Disclosed ownership: 8.4%.
- Date of event: 30 Jun 2025.
T. Rowe Price Investment Management, Inc. - 30 Jun 2025 SCHEDULE 13G Report for KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Symbol
- KPTI
- Shares outstanding
- 8,675,786 shares
- Disclosed Ownership
- 728,766 shares
- Ownership
- 8.4%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Aug 2025, 12:12:13 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 07 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 8.4% ownership in KARYOPHARM THERAPEUTICS INC COMMON STOCK (KPTI) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 12:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 8.4% | 728,766 | 728,766 | 0 | Ellen York | Vice President |